Compare ENTX & OWLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENTX | OWLT |
|---|---|---|
| Founded | 2010 | 2013 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 147.4M | 148.4M |
| IPO Year | 2015 | 2020 |
| Metric | ENTX | OWLT |
|---|---|---|
| Price | $3.01 | $5.55 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $9.00 | ★ $17.50 |
| AVG Volume (30 Days) | ★ 341.2K | 215.5K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.22 | N/A |
| Revenue | $42,000.00 | ★ $105,708,000.00 |
| Revenue This Year | N/A | $22.81 |
| Revenue Next Year | N/A | $20.45 |
| P/E Ratio | $13.45 | ★ N/A |
| Revenue Growth | N/A | ★ 35.43 |
| 52 Week Low | $0.91 | $4.19 |
| 52 Week High | $4.20 | $16.94 |
| Indicator | ENTX | OWLT |
|---|---|---|
| Relative Strength Index (RSI) | 54.89 | 55.43 |
| Support Level | $2.71 | $5.02 |
| Resistance Level | $3.10 | $6.08 |
| Average True Range (ATR) | 0.17 | 0.22 |
| MACD | -0.01 | 0.05 |
| Stochastic Oscillator | 70.21 | 90.02 |
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
Owlet Inc is engaged in providing a digital parenting platform that aims to give parents real-time data and insights to help parents feel more calm and confident. Its diversified portfolio of products includes Owlet Smart Sock, the first baby monitor to track an infant's oxygen levels, heart rate, and sleep trends; the Owlet Cam, which turns any smartphone into a baby monitor with high-definition clarity; the Owlet Monitor Duo, which offers the intelligence of the Owlet Smart Sock paired with the Owlet Cam; and Owlet Dream Lab, an interactive online program designed to be a parent's guide to building healthy sleep habits for their infants.